{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:46:52Z","timestamp":1782863212065,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12163-5","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:49:01Z","timestamp":1782859741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The interplay of bosentan and finerenone in amelioration of cardiac dysfunction within benign prostatic hyperplasia in rats"],"prefix":"10.1007","volume":"53","author":[{"given":"Marwa Monier Mahmoud","family":"Refaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3787-1823","authenticated-orcid":false,"given":"Asmaa A.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa A.","family":"Muhammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Abdel Naby","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Fathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aml Mohamed","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda S.","family":"Sherkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia N.","family":"Beshay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Alam-Eldin Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar Hisham","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"12163_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12894-023-01371-x","volume":"23","author":"II Bello","year":"2023","unstructured":"Bello II, Omigbodun A, Morhason-Bello I (2023) Common salt aggravated pathology of testosterone-induced benign prostatic hyperplasia in adult male Wistar rat. BMC Urol 23:207","journal-title":"BMC Urol"},{"key":"12163_CR2","doi-asserted-by":"publisher","unstructured":"Hata J, Harigane Y, Matsuoka K, Akaihata H, Yaginuma K, Meguro S et al (2023) Mechanism of androgen-independent stromal proliferation in benign prostatic hyperplasia. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241411634","DOI":"10.3390\/ijms241411634"},{"key":"12163_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jare.2023.04.006","volume":"57","author":"B-R Jin","year":"2024","unstructured":"Jin B-R, Kim H-J, Na J-H, Lee W-K, An H-J (2024) Targeting benign prostate hyperplasia treatments: AR\/TGF-\u03b2\/NOX4 inhibition by apocynin suppresses inflammation and proliferation. J Adv Res 57:135\u2013147","journal-title":"J Adv Res"},{"key":"12163_CR4","doi-asserted-by":"publisher","first-page":"2304274","DOI":"10.1002\/advs.202304274","volume":"11","author":"D Lin","year":"2024","unstructured":"Lin D, Luo C, Wei P, Zhang A, Zhang M, Wu X et al (2024) YAP1 recognizes inflammatory and mechanical cues to exacerbate benign prostatic hyperplasia via promoting cell survival and fibrosis. Adv Sci 11:2304274","journal-title":"Adv Sci"},{"key":"12163_CR5","doi-asserted-by":"publisher","first-page":"102816","DOI":"10.1016\/j.redox.2023.102816","volume":"65","author":"B-R Jin","year":"2023","unstructured":"Jin B-R, Lim C-Y, Kim H-J, Lee M, An H-J (2023) Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR\u2013NLRP3 pathway. Redox Biol 65:102816","journal-title":"Redox Biol"},{"key":"12163_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40779-024-00533-8","volume":"11","author":"S-Y Wang","year":"2024","unstructured":"Wang S-Y, Cai Y, Hu X, Li F, Qian X-H, Xia L-Y et al (2024) P. gingivalis in oral-prostate axis exacerbates benign prostatic hyperplasia via IL-6\/IL-6R pathway. Military Med Res 11:30","journal-title":"Military Med Res"},{"issue":"12","key":"12163_CR7","first-page":"e32141","volume":"14","author":"RR SK SC","year":"2022","unstructured":"SK SC RR, Nachiappa Ganesh R, Cleistanthins A (2022) Ameliorate testosterone-induced benign prostatic hyperplasia in castrated rats by regulating apoptosis and cell differentiation. Cureus 14(12):e32141","journal-title":"Cureus"},{"key":"12163_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000486349","volume":"27","author":"IO Ishola","year":"2018","unstructured":"Ishola IO, Yemitan KO, Afolayan OO, Anunobi CC, Durojaiye TE (2018) Potential of moringa oleifera in the treatment of benign prostate hyperplasia: Role of antioxidant defence systems. Med Princ Pract 27:15\u201322","journal-title":"Med Princ Pract"},{"key":"12163_CR9","doi-asserted-by":"publisher","unstructured":"Sarbishegi M, Khani M, Salimi S, Valizadeh M, Sargolzaei Aval F (2016) Antiproliferative and antioxidant effects of withania coagulans extract on benign prostatic hyperplasia in rats. Nephrourol Mon 8. https:\/\/doi.org\/10.5812\/numonthly.33180","DOI":"10.5812\/numonthly.33180"},{"key":"12163_CR10","first-page":"1116","volume":"24","author":"M-Y Liu","year":"2018","unstructured":"Liu M-Y, Chi N-J, Feng J, Shi X-P, Wen A-D (2018) [Ruyi Jinhuang Plaster suppresses BPH by reducing the expressions of P38, JNK2, NF-\u043aBP65 and STAT3 in the prostate tissue of rats]. Zhonghua Nan Ke Xue 24:1116\u20131121","journal-title":"Zhonghua Nan Ke Xue"},{"key":"12163_CR11","doi-asserted-by":"crossref","unstructured":"Duru R, Njoku O, Maduka I (2014) Oxidative stress indicators in patients with prostate disorders in enugu, South-East Nigeria. BioMed Research International 1\u20136","DOI":"10.1155\/2014\/313015"},{"key":"12163_CR12","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.2147\/IJN.S202645","volume":"14","author":"B Al-Trad","year":"2019","unstructured":"Al-Trad B, Aljabali A, Al-Zoubi M, Shehab M, Omari S (2019) Effect of gold nanoparticles treatment on the testosterone-induced benign prostatic hyperplasia in rats. IJN 14:3145\u20133154","journal-title":"IJN"},{"key":"12163_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jep.2014.09.025","volume":"157","author":"X Yang","year":"2014","unstructured":"Yang X, Yuan L, Xiong C, Yin C, Ruan J (2014) Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol 157:105\u2013113","journal-title":"J Ethnopharmacol"},{"key":"12163_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/01480545.2019.1635149","volume":"44","author":"SZ Basha","year":"2021","unstructured":"Basha SZ, Mohamed GA, Abdel-Naim AB, Hasan A, Abdel-Lateff A (2021) Cucurbitacin E glucoside from Citrullus colocynthis inhibits testosterone-induced benign prostatic hyperplasia in mice. Drug Chem Toxicol 44:533\u2013543","journal-title":"Drug Chem Toxicol"},{"key":"12163_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00431-025-06019-6","volume":"184","author":"A De Vadder","year":"2025","unstructured":"De Vadder A, Lemloh L, Bo B, Hale L, Patel N, Mueller A et al (2025) Bosentan as adjunctive therapy in neonates with congenital diaphragmatic hernia-associated pulmonary hypertension: a case series. Eur J Pediatr 184:198","journal-title":"Eur J Pediatr"},{"key":"12163_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1186\/s12887-024-05107-0","volume":"24","author":"A Kallimath","year":"2024","unstructured":"Kallimath A, Deshpande S, Singh P, Garegrat R, Lakshminrusimha S, Maheshwari R et al (2024) Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial. BMC Pediatr 24:698","journal-title":"BMC Pediatr"},{"key":"12163_CR17","doi-asserted-by":"publisher","first-page":"153042","DOI":"10.1016\/j.tox.2021.153042","volume":"465","author":"MMM Refaie","year":"2022","unstructured":"Refaie MMM, Abdel-Gaber SA, Rahman SAAE, Hafez SMNA, Khalaf HM (2022) Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity. Toxicology 465:153042","journal-title":"Toxicology"},{"key":"12163_CR18","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/xbdtb5","author":"P Bearzi","year":"2023","unstructured":"Bearzi P, Navarini L, Currado D, Marino A, Minerba M, Salvolini C et al (2023) Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis. Clin Exp Rheumatol. https:\/\/doi.org\/10.55563\/clinexprheumatol\/xbdtb5","journal-title":"Clin Exp Rheumatol"},{"key":"12163_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/DMSO.S503133","volume":"18","author":"J Shu","year":"2025","unstructured":"Shu J, Chen D, Chen W, Zhang X, Wang S, Chong N et al (2025) Finerenone ameliorates high glucose-induced podocytes epithelial-mesenchymal transition through the regulation of kr\u00fcppel-like factor 5 in diabetic nephropathy. DMSO 18:637\u2013651","journal-title":"DMSO"},{"key":"12163_CR20","doi-asserted-by":"publisher","first-page":"167968","DOI":"10.1016\/j.bbadis.2025.167968","volume":"1871","author":"Z Xu","year":"2025","unstructured":"Xu Z, Li X, Long Y, He A, Zou Z, Wang G et al (2025) Finerenone ameliorates high-fat-induced myocardial lipotoxicity by suppressing ferroptosis through augmenting the system Xc\u2013\/GSH synthesis pathway. Biochimica et Biophysica Acta (BBA) -. Mol Basis Disease 1871:167968","journal-title":"Mol Basis Disease"},{"key":"12163_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485","journal-title":"N Engl J Med"},{"key":"12163_CR22","doi-asserted-by":"crossref","unstructured":"Buege JA, Aust SD (1978) [30] Microsomal lipid peroxidation. Methods in enzymology. Elsevier, pp 302\u2013310","DOI":"10.1016\/S0076-6879(78)52032-6"},{"key":"12163_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0304-4165(79)90289-7","volume":"582","author":"M Moron","year":"1979","unstructured":"Moron M, Depierre J, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochimica et Biophysica Acta (BBA) -. Gen Subj 582:67\u201378","journal-title":"Gen Subj"},{"key":"12163_CR24","doi-asserted-by":"crossref","unstructured":"Bancroft JD, Layton C (2018) 10\u2014The hematoxylins and eosin. Bancroft\u2019s Theory and Practice of Histological Techniques, 8th ed; Suvarna, SK, Layton, C, Bancroft, JD, Eds ;: 126\u2013138","DOI":"10.1016\/B978-0-7020-6864-5.00010-4"},{"key":"12163_CR25","first-page":"372","volume":"45","author":"H Hashem","year":"2022","unstructured":"Hashem H, Amin MA (2022) The effect of zinc nanoparticles on adult rat prostate gland and the possible protective role of rutin: Histological and biochemical study. Egypt J Histol 45:372\u2013385","journal-title":"Egypt J Histol"},{"key":"12163_CR26","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1177\/1535370216643418","volume":"241","author":"DS El-Agamy","year":"2016","unstructured":"El-Agamy DS, Abo-Haded HM, Elkablawy MA (2016) Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats. Exp Biol Med (Maywood) 241:1577\u20131587","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"12163_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pros.2990250206","volume":"25","author":"Y Hasui","year":"1994","unstructured":"Hasui Y, Marutsuka K, Asada Y, Ide H, Nishi S, Osada Y (1994) Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 25(2):91\u201396. https:\/\/doi.org\/10.1002\/pros.2990250206","journal-title":"Prostate"},{"key":"12163_CR28","doi-asserted-by":"crossref","unstructured":"Kielkopf CL, Bauer W, Urbatsch IL (2020) Bradford assay for determining protein concentration. Cold Spring Harb Protoc. pdb. https:\/\/prot102269","DOI":"10.1101\/pdb.prot102269"},{"issue":"2","key":"12163_CR29","doi-asserted-by":"publisher","first-page":"e70085","DOI":"10.1111\/cpr.70085","volume":"59","author":"D Lin","year":"2026","unstructured":"Lin D, Wei P, Zhang M, Li K, Li L, Li Z, Luo C, Kuang W, Cui K, Chen Z (2026) Targeting ROCK1\/YAP1 Axis ameliorates inflammation-induced prostatic hyperplasia via stabilising sirt1-dependent mitochondrial dynamics. Cell Prolif 59(2):e70085. https:\/\/doi.org\/10.1111\/cpr.70085","journal-title":"Cell Prolif"},{"issue":"1","key":"12163_CR30","doi-asserted-by":"publisher","first-page":"11651","DOI":"10.1038\/s41598-026-47374-0","volume":"16","author":"G Alomari","year":"2026","unstructured":"Alomari G, Al-Trad B, Qar J, Tahat L, Abu Haija Y, Al-Najjar A, Albokhadaim I, Shousha S, Alameen AO, Shukry M (2026) Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling. Sci Rep 16(1):11651. https:\/\/doi.org\/10.1038\/s41598-026-47374-0","journal-title":"Sci Rep"},{"issue":"3","key":"12163_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/ph19030453","volume":"19","author":"P Kumbukgahadeniya","year":"2026","unstructured":"Kumbukgahadeniya P, Baek EB, Lee SH, Ha DI, Hong EJ, Song JY, Yoon WK, Kwun HJ (2026) Calamagrostis arundinacea extract mitigates testosterone induced prostatic hyperplasia in rats. Pharmaceuticals (Basel) 19(3):453. https:\/\/doi.org\/10.3390\/ph19030453","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"12163_CR32","doi-asserted-by":"publisher","first-page":"9937","DOI":"10.1007\/s00210-026-05044-y","volume":"399","author":"AK Ali","year":"2026","unstructured":"Ali AK, Abu-Raghif AR, Ridha-Salman H (2026) Uroprotective effect of diarylpropionitrile versus finasteride on rat model of testosterone-induced prostatic hyperplasia. Naunyn Schmiedebergs Arch Pharmacol 399(7):9937\u20139953. https:\/\/doi.org\/10.1007\/s00210-026-05044-y","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"12163_CR33","doi-asserted-by":"publisher","first-page":"614897","DOI":"10.3389\/fphar.2020.614897","volume":"11","author":"BG Eid","year":"2020","unstructured":"Eid BG, Abdel-Naim AB (2020) Piceatannol attenuates testosterone-induced benign prostatic hyperplasia in rats by modulation of Nrf2\/HO-1\/NF\u03baB Axis. Front Pharmacol 11:614897","journal-title":"Front Pharmacol"},{"key":"12163_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/nu16081189","volume":"16","author":"SM Lee","year":"2024","unstructured":"Lee SM, Lee SM, Song J (2024) Effects of taraxaci herba (Dandelion) on testosterone propionate-induced benign prostatic hyperplasia in rats. Nutrients 16:1189","journal-title":"Nutrients"},{"issue":"7","key":"12163_CR35","doi-asserted-by":"publisher","first-page":"10323","DOI":"10.1007\/s00210-026-04998-3","volume":"399","author":"SSA El-Hameed","year":"2026","unstructured":"El-Hameed SSA, Matouk AI, Ibrahim ARN, El-Daly M (2026) Mechanistic insights into the anti-benign prostatic hyperplasia effect of dihydromyricetin via suppression of the 5-AR\/TGF-\u03b21\/Smad2 axis. Naunyn Schmiedebergs Arch Pharmacol 399(7):10323\u201310339. https:\/\/doi.org\/10.1007\/s00210-026-04998-3Epub 2026 Feb 3. PMID: 41629614; PMCID: PMC13152920","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"12163_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12906-021-03472-2","volume":"21","author":"E Shabani","year":"2021","unstructured":"Shabani E, Kalantari H, Kalantar M, Goudarzi M, Mansouri E, Kalantar H (2021) Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats. BMC Complement Med Ther 21:301","journal-title":"BMC Complement Med Ther"},{"key":"12163_CR37","unstructured":"Miah MA, Sathi MA, Hasib MG, Rahman M, Mahmud N, Shill MC, Reza HM, Hossain M, Rahman MM, Mostaid MS (2026) Rice bran oil ameliorates the symptoms of benign prostatic hyperplasia in male Wistar rats. Avicenna J Phytomed May-Jun 16(3):458\u2013472. doi: 10.22038\/ajp.2025.26244. PMID: 42153017; PMCID: PMC13180239"},{"issue":"4","key":"12163_CR38","doi-asserted-by":"publisher","first-page":"e70845","DOI":"10.1002\/jbt.70845","volume":"40","author":"M Kotaru","year":"2026","unstructured":"Kotaru M, Ranjan Das N (2026) Capsaicin mitigates insulin resistance-driven prostate hyperplasia Via IGF-1 signalling modulation in HFD\u2009+\u2009STZ Rat Model. J Biochem Mol Toxicol 40(4):e70845. PMID: 41987603; PMCID: PMC13084211 https:\/\/doi.org\/10.1002\/jbt.70845 PMID: 41987603; PMCID: PMC13084211","journal-title":"J Biochem Mol Toxicol"},{"key":"12163_CR39","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P et al (2021) Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol 52:642\u2013652","journal-title":"Am J Nephrol"},{"key":"12163_CR40","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","volume":"79","author":"L Tu","year":"2022","unstructured":"Tu L, Thuillet R, Perrot J, Ottaviani M, Ponsardin E, Kolkhof P et al (2022) Mineralocorticoid receptor antagonism by finerenone attenuates established pulmonary hypertension in rats. Hypertension 79:2262\u20132273","journal-title":"Hypertension"},{"key":"12163_CR41","doi-asserted-by":"publisher","first-page":"115661","DOI":"10.1016\/j.biopha.2023.115661","volume":"168","author":"M Sanz-G\u00f3mez","year":"2023","unstructured":"Sanz-G\u00f3mez M, Manzano-Lista FJ, Vega-Mart\u00edn E, Gonz\u00e1lez-Moreno D, Alcal\u00e1 M, Gil-Ortega M et al (2023) Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors. Biomed Pharmacother 168:115661","journal-title":"Biomed Pharmacother"},{"key":"12163_CR42","doi-asserted-by":"publisher","first-page":"e032971","DOI":"10.1161\/JAHA.123.032971","volume":"13","author":"I Lima Posada","year":"2024","unstructured":"Lima Posada I, Souli\u00e9 M, Stephan Y, Palacios Ramirez R, Bonnard B, Nicol L et al (2024) Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease. JAHA 13:e032971","journal-title":"JAHA"},{"key":"12163_CR43","doi-asserted-by":"publisher","first-page":"e157165","DOI":"10.1172\/JCI157165","volume":"134","author":"A Abedini","year":"2024","unstructured":"Abedini A, S\u00e1nchez-Navaro A, Wu J, Kl\u00f6tzer KA, Ma Z, Poudel B et al (2024) Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists. J Clin Invest 134:e157165","journal-title":"J Clin Invest"},{"key":"12163_CR44","doi-asserted-by":"publisher","first-page":"115975","DOI":"10.1016\/j.bcp.2023.115975","volume":"220","author":"M Zhou","year":"2024","unstructured":"Zhou M, Zheng S, Chen C, Li X, Zhang Q, Zhao Y et al (2024) Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR. Biochem Pharmacol 220:115975","journal-title":"Biochem Pharmacol"},{"key":"12163_CR45","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","volume":"26","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ et al (2024) Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail 26:1324\u20131333","journal-title":"Eur J Heart Fail"},{"key":"12163_CR46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474\u2013484","journal-title":"Eur Heart J"},{"key":"12163_CR47","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3390\/ijms26136294","volume":"26","author":"M Esteves-Monteiro","year":"2025","unstructured":"Esteves-Monteiro M, Vitorino-Oliveira C, Castanheira-Moreira J, Ferreira-Duarte M, Dias-Pereira P, Costa VM et al (2025) Differential effects of losartan and finerenone on diabetic remodeling, oxidative stress and ACE activity in the gastrointestinal tract of streptozotocin-induced diabetic rats. IJMS 26:6294","journal-title":"IJMS"},{"key":"12163_CR48","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179:3220\u20133234","journal-title":"Br J Pharmacol"},{"key":"12163_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diff.2011.04.006","volume":"82","author":"TM Nicholson","year":"2011","unstructured":"Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 82:184\u2013199","journal-title":"Differentiation"},{"key":"12163_CR50","unstructured":"Ambali MP, Doshi MA, Ganga GM, Kanetkar SR, Kakade SV (2018) Study of mucin histochemistry in benign hyperplasia and malignant lesions of human prostate gland"},{"issue":"7","key":"12163_CR51","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/medicina61071298","volume":"61","author":"\u015eM Demir\u00f6z","year":"2025","unstructured":"Demir\u00f6z \u015eM, K\u00fc\u00e7\u00fck A, Tekin E, S\u00f6ylemez S, Y\u0131lmaz H, Sezen \u015eC, Atl\u0131 M, Demirta\u015f H, \u00d6zer A, \u00dcnal Y, Arslan M (2025) Cardioprotective effects of bosentan in rats subjected to lung ischemia-reperfusion injury. Med (Kaunas) 61(7):1298. https:\/\/doi.org\/10.3390\/medicina61071298","journal-title":"Med (Kaunas)"},{"issue":"1","key":"12163_CR52","doi-asserted-by":"publisher","first-page":"tfaf007","DOI":"10.1093\/toxres\/tfaf007","volume":"14","author":"RK Attarbashee","year":"2025","unstructured":"Attarbashee RK, Hamodat HF, Mammdoh JK, Ridha-Salman H (2025) The Possible effect of Bosentan on the methotrexate-induced salivary gland changes in male rats: histological and Immunohistochemical study. Toxicol Res (Camb) 14(1):tfaf007. https:\/\/doi.org\/10.1093\/toxres\/tfaf007","journal-title":"Toxicol Res (Camb)"},{"issue":"6","key":"12163_CR53","doi-asserted-by":"publisher","first-page":"8821","DOI":"10.1007\/s00210-025-04935-w","volume":"399","author":"SS Karcioglu","year":"2026","unstructured":"Karcioglu SS, Halici Z, Cadirci E, Toktay E (2026) Investigation of endothelin-1 receptor antagonist bosentan in a rat endometriosis model. Naunyn Schmiedebergs Arch Pharmacol 399(6):8821\u20138835. https:\/\/doi.org\/10.1007\/s00210-025-04935-w","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"12163_CR54","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2147\/DDDT.S510885","volume":"19","author":"H Demirta\u015f","year":"2025","unstructured":"Demirta\u015f H, \u00d6zer A, G\u00fclcan MB, Y\u0131\u011fman Z, K\u00fc\u00e7\u00fck A, Tekin E, \u00dcnal Y, Dursun AD, Da\u011fl\u0131 A, Arslan M (2025) Protective Effects of bosentan via endothelin receptor antagonism in experimental ischemia-reperfusion injury in the lower limb of rats. Drug Des Devel Ther 19:1561\u20131573. https:\/\/doi.org\/10.2147\/DDDT.S510885","journal-title":"Drug Des Devel Ther"},{"key":"12163_CR55","doi-asserted-by":"publisher","unstructured":"Al-Kadi A, Anter AF, Rofaeil RR, Sayed-Ahmed MM, Hafez SMNA, Ahmed AF (2025) Endothelin system blockade extenuates sepsis-induced acute heart and kidney injuries via modulating ET-1\/Klotho\/p38-MAPK. Clin Exp Pharmacol Physiol. 52(6):e70042. PMID: 40228821 PMID: 40228821 https:\/\/doi.org\/10.1111\/1440-1681.70042. PMID: 40228821","DOI":"10.1111\/1440-1681.70042"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12163-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:49:17Z","timestamp":1782859757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12163-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12163"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12163-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1059"}}